Merck (MRK) and its partner NGM Biopharmaceuticals hope to deliver on a potential treatment for non-alcoholic steatohepatitis and type 2 diabetes. This is what both companies showed when some preliminary data was released for a study using MK-3655 to treat patients with non-alcoholic fatty liver disease ((NAFLD)). There was a new updated data released from the study at the 79th Scientific Sessions of the American Diabetes Association ((ADA)). With promising preliminary data, it is expected that MK-3655 will be moved into a phase 2 study. The hope here lies not only to develop a new